When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy
暂无分享,去创建一个
[1] R. Terkeltaub,et al. Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management. , 2022, NEJM evidence.
[2] P. Tugwell,et al. Serum Urate as a Proposed Surrogate Outcome Measure in Gout Trials: From the OMERACT Working Group. , 2021, Seminars in Arthritis and Rheumatism.
[3] M. Hudgens,et al. Interpreting the Results of Intention-to-Treat, Per-Protocol, and As-Treated Analyses of Clinical Trials. , 2021, JAMA.
[4] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[5] M. Kolber,et al. Treat‐to‐Target in Gout Management? Comment on the Article by FitzGerald et al , 2020, Arthritis & rheumatology.
[6] W. Taylor,et al. The experience of a gout flare: a meta-synthesis of qualitative studies. , 2020, Seminars in arthritis and rheumatism.
[7] G. Guyatt,et al. 2020 American College of Rheumatology Guideline for the Management of Gout , 2020, Arthritis & rheumatology.
[8] M. Doherty,et al. Implication of nurse intervention on engagement with urate-lowering drugs: A qualitative study of participants in a RCT of nurse led care , 2019, Joint, bone, spine : revue du rhumatisme.
[9] L. Duley,et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial , 2018, The Lancet.
[10] J. Singh,et al. Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis. , 2018, Seminars in arthritis and rheumatism.
[11] M. Mayes,et al. Myeloablative Autologous Stem‐Cell Transplantation for Severe Scleroderma , 2018, The New England journal of medicine.
[12] A. Taniguchi,et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study , 2017, Annals of the rheumatic diseases.
[13] A. Worsley,et al. A Meta-Synthesis of Qualitative Studies Exploring Men’s Sense of Masculinity Post–Prostate Cancer Treatment , 2017, Cancer nursing.
[14] James M Robins,et al. Per-Protocol Analyses of Pragmatic Trials. , 2017, The New England journal of medicine.
[15] R. Terkeltaub,et al. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) , 2017, Nature Reviews Rheumatology.
[16] R. McLean. The Long and Winding Road to Clinical Guidelines on the Diagnosis and Management of Gout , 2017, Annals of Internal Medicine.
[17] T. Mikuls,et al. To Treat or Not to Treat (to Target) in Gout , 2017, Annals of Internal Medicine.
[18] A. Qaseem,et al. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. , 2017, Annals of internal medicine.
[19] K. Saag,et al. Lesinurad Combined With Allopurinol: A Randomized, Double‐Blind, Placebo‐Controlled Study in Gout Patients With an Inadequate Response to Standard‐of‐Care Allopurinol (a US‐Based Study) , 2017, Arthritis & rheumatology.
[20] Hyon K. Choi,et al. Editorial: Do Not Let Gout Apathy Lead to Gouty Arthropathy , 2016, Arthritis & rheumatology.
[21] A. So,et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study) , 2016, Annals of the rheumatic diseases.
[22] F. Becce,et al. 2016 updated EULAR evidence-based recommendations for the management of gout , 2014, Annals of the rheumatic diseases.
[23] J. Lieberman,et al. A Randomized, Controlled Trial of Total Knee Replacement. , 2016, The New England journal of medicine.
[24] M. Hernán,et al. Why post‐progression survival and post‐relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials , 2015, International journal of cancer.
[25] B. Griffiths,et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. , 2014, JAMA.
[26] James M Robins,et al. Randomized Trials Analyzed as Observational Studies , 2013, Annals of Internal Medicine.
[27] G. Yancopoulos,et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. , 2013, Rheumatology.
[28] Charles King,et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia , 2012, Arthritis care & research.
[29] W. White,et al. Pegloticase and Chronic Gout—Reply , 2011 .
[30] P. Lipsky,et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. , 2011, JAMA.
[31] A. So,et al. Extended Report , 2022 .
[32] U. Dafni. Landmark Analysis at the 25-Year Landmark Point , 2011, Circulation. Cardiovascular quality and outcomes.
[33] R. Wortmann,et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. , 2010, Clinical therapeutics.
[34] J. Singh,et al. Outcome Domains for Studies of Acute and Chronic Gout , 2009, The Journal of Rheumatology.
[35] J. Geddes,et al. What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.
[36] F. Perez-Ruiz,et al. Treating to target: a strategy to cure gout. , 2009, Rheumatology.
[37] P. Macdonald,et al. Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy , 2008, Nucleosides, nucleotides & nucleic acids.
[38] H. Schumacher,et al. The practical management of gout. , 2008, Cleveland Clinic journal of medicine.
[39] C. Kwoh,et al. Gout in ambulatory care settings in the United States. , 2008, The Journal of rheumatology.
[40] F. Martinon,et al. Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.
[41] H. Schumacher,et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. , 2005, The New England journal of medicine.
[42] M. Abel,et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. , 2004, The Journal of rheumatology.
[43] G. Hollingworth,et al. Comparison of injection techniques for shoulder pain: results of a double blind, randomised study. , 1983, British medical journal.
[44] E. Glaser. The randomized clinical trial. , 1972, The New England journal of medicine.
[45] A. Gutman,et al. EFFECT OF ALLOPURINOL (4-HYDROXYPYRAZOLO-(3,4-D)PYRIMIDINE) ON SERUM AND URINARY URIC ACID IN PRIMARY AND SECONDARY GOUT. , 1964, The American journal of medicine.
[46] D. Mccarty,et al. ACUTE ARTHRITIS IN MAN AND DOG AFTER INTRASYNOVIAL INJECTION OF SODIUM URATE CRYSTALS , 1962 .